

COMMUNICATION

Fluorogenic label to quantify the cytosolic delivery of macromolecules†

Cite this: *Mol. BioSyst.*, 2013, **9**, 339

Received 4th December 2012,
Accepted 10th January 2013

DOI: 10.1039/c3mb25552b

www.rsc.org/molecularbiosystems

Tzu-Yuan Chao‡^a and Ronald T. Raines*^{ab}

The delivery of a macromolecule to the cytosol of human cells is assessed by using a pendant di-*O*-glycosylated derivative of fluorescein. Its fluorescence is unmasked by *Escherichia coli* β -galactosidase installed in the cytosol. Background is diminished by using RNAi to suppress the expression of *GLB1*, which encodes a lysosomal β -galactosidase. This strategy was used to quantify the cytosolic entry of a highly cationic protein, ribonuclease A.

The cytosol of mammalian cells is the intended destination for many proteins and other macromolecules of interest.¹ Typically, delivery entails endocytosis, followed by translocation from an endosomal compartment to the cytosol. Uptake into endosomes can be facilitated by a cationic appendage² or graft,^{3,4} and can be assessed with a pendant fluorogenic probe that is unmasked by an endosomal esterase.^{5–8} But it is the next step, entailing traversal of a phospholipid bilayer, that is the major hurdle to cytosolic delivery.⁹

Endosome-to-cytosol translocation is a rare event and thus difficult to assess.^{10,11} Two strategies are evident for distinguishing the cytosolic pool of internalized molecules from the endosomal pool. One is to separate membrane-bound compartments from the cytosol by subcellular fractionation. This method requires cell lysis, and is thus inapplicable to live cells or high-throughput screens. A second method relies on the modification of a latent probe, such that macromolecules that reach the cytosol are differentiated from those in endosomes. Previous strategies for measuring translocation to the cytosol have relied on fluorescence resonance energy transfer (FRET), either by monitoring FRET between a preinstalled cytosolic fluorescent protein and a fluorophore-tagged peptide,¹² or by monitoring the unquenching

of fluorescence of a pair of disulfide-linked fluorophores.¹³ Although these strategies did overcome the difficulty of excluding signals from endocytic compartments, they suffer from a high background.

To avoid the background that accompanies chemical reactions, we sought an enzyme–substrate pair that was orthogonal to human cells. We reasoned that macromolecules tagged with fluorescein di- β -*D*-galactopyranoside (FDG) could be unmasked by *Escherichia coli* β -galactosidase (β -gal) produced by heterologous expression in the cytosol (Fig. 1).¹⁴ As a model protein, we chose bovine pancreatic ribonuclease (RNase A), which has well-established physicochemical properties.^{15–17} Like other highly cationic proteins,^{3,4} RNase A ($pI = 9.33$ ¹⁸) is taken up readily by mammalian cells.^{19–22}

We sought a means to conjugate FDG to RNase A. Sulfhydryl groups are readily alkylated by a variety of electrophiles.




Fig. 1 Strategy for detecting the entry of an exogenous protein into the cytosol of a human cell. A protein with a pendant fluorogenic probe is internalized by endocytosis. The conjugate is not fluorescent until hydrolyzed by β -galactosidase installed in the cytosol by transfection of a plasmid, which directs the concomitant expression of the monomeric red fluorescent protein (mRFP).

^a Department of Biochemistry, University of Wisconsin–Madison, 433 Babcock Drive, Madison, WI 53706, USA. E-mail: rtaines@wisc.edu

^b Department of Chemistry, University of Wisconsin–Madison, 1101 University Avenue, Madison, WI 53706, USA

† Electronic supplementary information (ESI) available: Experimental procedures. See DOI: 10.1039/c3mb25552b

‡ Present address: Novo Nordisk China R&D, No. 29 Life Science Park Road, Changping District, Beijing 102206, China.




Fig. 2 Strategy for conjugating fluorescein di-β-D-galactopyranoside (FDG) to bovine pancreatic ribonuclease (RNase A). The linkage is made via a cysteine residue installed at position 19 of RNase A by site-directed mutagenesis.

Wild-type RNase A has no sulfhydryl groups, so we used site-directed mutagenesis to create the A19C variant, which has a cysteine residue in a solvent-exposed surface loop.²³ We alkylated its nascent sulfhydryl group with 5-chloromethylfluorescein di-β-D-galactopyranoside (CMDFG) to create FDG-RNase A (Fig. 2).

We assessed the hydrolytic stability of FDG-RNase A and its ability to be a substrate for β-gal. We found that the fluorescence of FDG-RNase A remains masked for ≥ 12 h at pH 7, as well as at pH 4 (Fig. S1A in the ESI[†]), which is close to that found in late endosomes. We also found that the fluorescence of FDG-RNase A increases by 10^2 -fold upon addition of β-gal (Fig. S1B in the ESI[†]), validating the conjugate as a substrate.

Next, we examined the hydrolytic stability of FDG-RNase A in unmodified HeLa cells, which are *lacZ*⁻. Surprisingly, extended incubation (24 h) resulted in substantial background fluorescence, suggesting that an endogenous human enzyme can catalyze the unmasking of FDG-RNase A. We suspected that the undesired activity could arise from a human β-galactosidase, GLB1, which is a 76 kDa lysosomal enzyme that is not homologous to β-gal.^{24,25}




Fig. 3 Stable HeLa *GLB1* knockdown clones with reduced background fluorescence. (A) Cell lysates from unmodified HeLa cells (control) and cells stably transfected with *GLB1*-targeting shRNA were analyzed by immunoblotting with an anti-*GLB1* antibody. (B) FDG-RNase A was incubated with unmodified HeLa cells and *GLB1* knockdown clones for 24 h at 37 °C. Mean values (±SE) are from flow cytometry of 20 000 live cells (≥ 3 populations).

We used RNAi to suppress the activity of GLB1. Specifically, we created HeLa cell clones that stably express a short hairpin RNA (shRNA) that targets *GLB1*.²⁵ To assess success, we incubated FDG-RNase A with three clones having decreased *GLB1* expression (Fig. 3A) and measured the ensuing fluorescence with flow cytometry (Fig. 3B). The *GLB1*-knockdown clones had 50–65% less background fluorescence than unmodified HeLa cells, indicating that GLB1 activity is responsible for most of the unmasking of FDG-RNase A in unmodified HeLa cells.

Then, we transfected *GLB1*-knockdown HeLa cells (clone 1) with a plasmid containing a *lacZ*-IRES-*mRFP* construct (Fig. 1). Here, the internal ribosomal entry site (IRES) correlates the expression of the monomeric red fluorescent protein (mRFP) and the *lacZ* gene. Thus, *lacZ*⁺ cells can be identified definitively by their mRFP fluorescence. The cytosolic entry of RNase A was determined by incubating FDG-RNase A with *lacZ*⁺ cells. In a control experiment, the same amount of ribonuclease conjugate was incubated with cells transfected with a plasmid containing IRES-*mRFP* but lacking *lacZ*.²⁶ The cytosolic influx of RNase A increases rapidly in *lacZ*⁺ cells (Fig. 4A). Levels of background fluorescence, as measured within *lacZ*⁻ cells, accounts for ~20% of the fluorescence of *lacZ*⁺ cells. These data are consistent with observations made by using fluorescence microscopy. As expected, we observed diffuse fluorescence in *lacZ*⁺ clone-1 HeLa cells, but little or no fluorescence in *lacZ*⁻ cells (Fig. 4B). Punctations likely arise from the




Fig. 4 Cellular uptake and cytosolic entry of RNase A. *lacZ*⁺ clone-1 HeLa cells were transfected with the *lacZ*-IRES-mRFP construct (Fig. 1). *lacZ*⁻ clone-1 HeLa cells were transfected with the same vector but containing an IRES-mRFP construct. (A) FDG-RNase A (5 μ M) was added to *lacZ*⁺ (●) and *lacZ*⁻ (○) cells. Mean values (\pm SE) are for green fluorescence from flow cytometry of 10 000 live cells (\geq 6 populations) that emit red fluorescence. Fluorescein-RNase A (5 μ M) was added to cells treated with bafilomycin A1 (0.10 μ M). Mean values (\pm SE) are for green fluorescence from flow cytometry of 10 000 live cells (\geq 6 populations). Inset: close-up of FDG-RNase A data. (B) FDG-RNase A (5 μ M) was incubated with *lacZ*⁺ and *lacZ*⁻ cells for 24 h at 37 $^{\circ}$ C. Blue dye, Hoechst 33342; scale bars, 10 μ m.

\sim 20% background fluorescence. These results illustrate that cytosolic entry of a protein can be assessed by using pendant FDG with *lacZ*⁺ human cells.

Next, we employed a simple fluorescein-RNase A conjugate¹⁹ to discern the fraction of internalized molecules that reach the cytosol. The conjugate acid of the fluorescein anion has $pK_a = 6.30$,²⁷ and loses fluorescence upon protonation. Accordingly, we used bafilomycin A1, which is a specific inhibitor of the vacuolar ATPase responsible for endosome acidification,^{20,28} to neutralize endosomes and enable an accurate measure of total fluorescein-RNase A uptake. The ensuing data indicate that the vast majority of this cationic protein is entrapped in endocytic vesicles (Fig. 4A). We estimate that only \sim 7% of the protein that enters cells is able to translocate to the cytosol in 24 h.

Finally, we extended our analysis by quantifying the RNase A molecules that reach the cytosol. Ribonucleases are promising chemotherapeutic agents. They have an innate ability to enter

the cytosol, where they catalyze RNA degradation if they can evade the resident ribonuclease inhibitor protein, which binds to RNase A with femtomolar affinity.^{29–33} Evasive RNase A variants inhibit the proliferation of human cancer cells with IC_{50} values in the high nanomolar range.³⁴ Using quantum dot calibration beads,³⁵ we found that the total fluorescence in *lacZ*⁺ cells upon incubation with 5 μ M FDG-RNase A for 24 h derives from $(3.5 \pm 0.2) \times 10^4$ molecules per cell. As noted above, \sim 80% of these fluorescent molecules are in the cytosol, and the remaining \sim 20% are in the large pool of endosomal FDG-RNase A (Fig. 4A). The volume of the cytosol in a HeLa cell is 940 μm^3 .³⁶ Accordingly, a 5 μ M dose of FDG-RNase A for 24 h results in a cytosolic concentration of \sim 50 nM. As the concentration of ribonuclease inhibitor in the cytosol is 4 μ M,³⁷ these data explain the inability of low concentrations of wild-type RNase A to manifest cytotoxicity—the efficiency of its translocation to the cytosol is too low to overcome the ribonuclease inhibitor protein.

This work was supported by Grants R01 CA073808 and R01 GM044783 (NIH). T.-Y.C. was supported by the Dr James Chieh-Hsia Mao Wisconsin Distinguished Graduate Fellowship. We are grateful to L. D. Lavis and J. E. Lomax for advice, and to D. C. DiMaio and B. Sugden for plasmids.

Notes and references

- 1 V. P. Torchilin, Recent approaches to intracellular delivery of drugs and DNA and organelle targeting, *Annu. Rev. Biophys. Biomol. Eng.*, 2006, **8**, 343–375.
- 2 P. A. Wender, W. C. Galliher, E. A. Goun, L. R. Jones and T. H. Pillow, The design of guanidinium-rich transporters and their internalization mechanisms, *Adv. Drug Delivery Rev.*, 2008, **60**, 452–472.
- 3 S. M. Fuchs and R. T. Raines, Arginine grafting to endow cell permeability, *ACS Chem. Biol.*, 2007, **2**, 167–170.
- 4 D. B. Thompson, J. J. Cronican and D. R. Liu, Engineering and identifying supercharged proteins for macromolecule delivery into mammalian cells, *Methods Enzymol.*, 2012, **503**, 293–319.
- 5 T. L. Huang, A. Székács, T. Uematsu, E. Kuwano, A. Parkinson and B. D. Hammock, Hydrolysis of carbonates, thiocarbonates, carbamates, and carboxylic esters of α -naphthol, β -naphthol, and *p*-nitrophenol by human, rat, and mouse liver carboxylesterases, *Pharm. Res.*, 1993, **10**, 639–648.
- 6 L. D. Lavis, T.-Y. Chao and R. T. Raines, Fluorogenic label for biomolecular imaging, *ACS Chem. Biol.*, 2006, **1**, 252–260.
- 7 L. D. Lavis and R. T. Raines, Bright ideas for chemical biology, *ACS Chem. Biol.*, 2008, **3**, 142–155.
- 8 L. Tian, Y. Yang, L. W. Wysocki, A. C. Arnold, A. Hu, B. Ravichandran, S. M. Sternson, L. L. Looger and L. D. Lavis, Selective esterase-ester pair for targeting small molecules with cellular specificity, *Proc. Natl. Acad. Sci. U. S. A.*, 2012, **109**, 4756–4761.

- 9 G. M. Larson and K. D. Lee, Macromolecular cytosolic delivery: Cell membranes as the primary obstacle, *Arch. Pharmacol. Res.*, 1998, **21**, 621–628.
- 10 K. D. Jensen, A. Nori, M. Tijerina, P. Kopeckova and J. Kopecek, Cytoplasmic delivery and nuclear targeting of synthetic macromolecules, *J. Controlled Release*, 2003, **87**, 89–105.
- 11 S. T. Henriques, M. N. Melo and M. Castanho, How to address CPP and AMP translocation? Methods to detect and quantify peptide internalization *in vitro* and *in vivo*, *Mol. Membr. Biol.*, 2007, **24**, 173–184.
- 12 S. R. Adams and R. Y. Tsien, *Imaging the influx of cell-penetrating peptides into the cytosol of individual live cells*, in *Handbook of Cell-Penetrating Peptides*, ed. U. Langel, 2nd edn, 2006, pp. 505–512.
- 13 J. C. Cheung, P. K. Chiaw, C. M. Deber and C. E. Bear, A novel method for monitoring the cytosolic delivery of peptide cargo, *J. Controlled Release*, 2009, **137**, 2–7.
- 14 A. Plovins, A. M. Alvarez, M. Ibanez, M. Molina and C. Nombela, Use of fluorescein-di- β -D-galactopyranoside (FDG) and C12-FDG as substrates for β -galactosidase detection by flow cytometry in animal, bacterial, and yeast cells, *Appl. Environ. Microbiol.*, 1994, **60**, 4638–4641.
- 15 R. T. Raines, Ribonuclease A, *Chem. Rev.*, 1998, **98**, 1045–1065.
- 16 G. R. Marshall, J. A. Feng and D. J. Kuster, Back to the future: Ribonuclease A, *Biopolymers*, 2008, **90**, 259–277.
- 17 C. M. Cuchillo, M. V. Nogués and R. T. Raines, *Biochemistry*, 2011, **50**, 7835–7841.
- 18 N. Ui, Isoelectric points and conformation of proteins. I. Effect of urea on the behavior of some proteins in isoelectric focusing, *Biochim. Biophys. Acta*, 1971, **229**, 567–581.
- 19 M. C. Haigis and R. T. Raines, Secretory ribonucleases are internalized by a dynamin-independent endocytic pathway, *J. Cell Sci.*, 2003, **116**, 313–324.
- 20 M. Rodríguez, G. Torrent, M. Bosch, F. Rayne, J.-F. Dubremetz, M. Ribó, A. Benito, M. Vilanova and B. Beaumelle, Intracellular pathway of Onconase that enables its delivery to the cytosol, *J. Cell Sci.*, 2007, **120**, 1405–1411.
- 21 T.-Y. Chao and R. T. Raines, Mechanism of ribonuclease A endocytosis: Analogies to cell-penetrating peptides, *Biochemistry*, 2010, **50**, 8374–8382.
- 22 T.-Y. Chao, L. D. Lavis and R. T. Raines, Cellular uptake of ribonuclease A relies on anionic glycans, *Biochemistry*, 2010, **49**, 10666–10673.
- 23 S. Kothandaraman, M. C. Hebert, R. T. Raines and M. L. Nibert, No role for pepstatin-A-sensitive acidic proteinase in reovirus infections of L or MDCK cells, *Virology*, 1998, **251**, 264–272.
- 24 A. G. W. Norden, L. L. Tennant and J. S. O'Brien, G_{M1} ganglioside β -galactosidase A, *J. Biol. Chem.*, 1974, **249**, 7969–7976.
- 25 B. Y. Lee, J. A. Han, J. S. Im, A. Morrone, K. Johung, D. DiMaio and E. S. Hwang, Senescence-associated β -galactosidase is lysosomal β -galactosidase, *Aging Cell*, 2006, **5**, 187–195.
- 26 Z. L. Pratt, J. Zhang and B. Sugden, The latent membrane protein 1 (LMP1) oncogene of Epstein-Barr virus can simultaneously induce and inhibit apoptosis in B cells, *J. Virol.*, 2012, **86**, 4380–4393.
- 27 L. D. Lavis, T. J. Rutkoski and R. T. Raines, Tuning the pK_a of fluorescein to optimize binding assays, *Anal. Chem.*, 2007, **79**, 6775–6782.
- 28 B. P. Crider, X.-S. Xie and D. K. Stone, Bafilomycin inhibits proton flow through the H^+ channel of vacuolar proton pumps, *J. Biol. Chem.*, 1994, **269**, 17379–17381.
- 29 P. A. Leland, L. W. Schultz, B.-M. Kim and R. T. Raines, Ribonuclease A variants with potent cytotoxic activity, *Proc. Natl. Acad. Sci. U. S. A.*, 1998, **95**, 10407–10412.
- 30 U. Arnold and R. Ulbrich-Hofmann, Natural and engineered ribonucleases as potential cancer therapeutics, *Biotechnol. Lett.*, 2006, **28**, 1615–1622.
- 31 J. E. Lee and R. T. Raines, Ribonucleases as novel chemotherapeutics: The ranpirinase example, *BioDrugs*, 2008, **22**, 53–58.
- 32 T. J. Rutkoski and R. T. Raines, Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity, *Curr. Pharm. Biotechnol.*, 2008, **9**, 185–199.
- 33 J. E. Lomax, C. H. Eller and R. T. Raines, Rational design and evaluation of mammalian ribonuclease cytotoxins, *Methods Enzymol.*, 2012, **502**, 273–290.
- 34 T. J. Rutkoski, E. L. Kurten, J. C. Mitchell and R. T. Raines, Disruption of shape-complementarity markers to create cytotoxic variants of ribonuclease A, *J. Mol. Biol.*, 2005, **354**, 41–54.
- 35 Y. Wu, S. K. Campos, G. P. Lopez, M. A. Ozburn, L. A. Sklar and T. Buranda, The development of quantum dot calibration beads and quantitative multicolor bioassays in flow cytometry and microscopy, *Anal. Biochem.*, 2007, **364**, 180–192.
- 36 A. Fujioka, K. Terai, R. E. Itoh, K. Aoki, T. Nakamura, S. Kuroda, E. Nishida and M. Matsuda, Mechanisms of signal transduction, *J. Biol. Chem.*, 2006, **281**, 8917–8926.
- 37 M. C. Haigis, E. L. Kurten and R. T. Raines, Ribonuclease inhibitor as an intracellular sentry, *Nucleic Acids Res.*, 2003, **31**, 1024–1032.